Superfund Research Program

Nipavan Chiamvimonvat

University of California-Davis
Division of Cardiovascular Physiology
GBSF 6315
Davis, California 95616
Phone: 530-754-7158
Email: nchiamvimonvat@ucdavis.edu

Projects

• University of California-Davis: Critical Role of Mitochondrial Oxidative Stress (MOS) in Chemical Induced Cardiac Toxicity (2017-2023)
• University of California-Davis: Interdisciplinary Training Core (1995-2023)

Patents

• Methods of Improving Cell-based Therapy

Publications

2023

• Thai PN, Ren L, Xu W, Overton J, Timofeyev V, Nader CE, Haddad MJ, Yang J, Gomes AV, Hammock BD, Chiamvimonvat N, Sirish P. 2023. Chronic diclofenac exposure increases mitochondrial oxidative stress, inflammatory mediators, and cardiac dysfunction. Cardiovasc Drugs Ther 37(1):25-37. doi:10.1007/s10557-021-07253-4 PMID:34499283 PMCID:PMC8904649

2021

• Lind L, Araujo JA, Barchowsky A, Belcher SM, Berridge BR, Chiamvimonvat N, Chiu WA, Cogliano VJ, Elmore S, Farraj AK, Gomes AV, McHale CM, Meyer-Tamaki KB, Posnack NG, Vargas HM, Yang X, Zeise L, Zhou C, Smith MT. 2021. Key characteristics of cardiovascular toxicants. Environ Health Perspect 129(9):95001. doi:10.1289/EHP9321 PMID:34558968 PMCID:PMC8462506

2020

• Sirish P, Thai PN, Lee JH, Yang J, Zhang X, Ren L, Li N, Timofeyev V, Lee KS, Nader CE, Rowland DJ, Yechikov S, Ganaga S, Young JN, Lieu DK, Yamoah EN, Hammock BD, Chiamvimonvat N. 2020. Suppression of inflammation and fibrosis using soluble epoxide hydrolase inhibitors enhances cardiac stem cell-based therapy. Stem Cells Transl Med doi:10.1002/sctm.20-0143 PMID:32790136

2017

• Frederich BJ, Timofeyev V, Thai PN, Haddad MJ, Poe AJ, Lau V, Moshref M, Knowlton AA, Sirish P, Chiamvimonvat N. 2017. Electrotaxis of cardiac progenitor cells, cardiac fibroblasts, and induced pluripotent stem cell-derived cardiac progenitor cells requires serum and is directed via PI3 ' K pathways. Heart Rhythm 14:1685-1692. doi:10.1016/j.hrthm.2017.06.038 PMID:28668623 PMCID:PMC5671891

2016

• Sirish P, Li N, Timofeyev V, Zhang X, Wang L, Yang J, Lee KS, Bettaieb A, Ma S, Lee JH, Su D, Lau V, Myers R, Lieu DK, Lopez JE, Young JN, Yamoah EN, Haj FG, Ripplinger C, Hammock BD, Chiamvimonvat N. 2016. Molecular mechanisms and new treatment paradigm for atrial fibrillation. Circ Arrhythm Electrophysiol 9(5):e003721-e003740. doi:10.1161/CIRCEP.115.003721 PMID:27162031 PMCID:PMC4869994

2015

• Harris TR, Bettaieb A, Kodani SD, Dong H, Myers R, Chiamvimonvat N, Haj FG, Hammock BD. 2015. Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. Toxicol Appl Pharmacol 286(2):102-111. doi:10.1016/j.taap.2015.03.022 PMID:25827057 PMCID:PMC4458210

2014

• Despa S, Sharma S, Harris TR, Dong H, Li N, Chiamvimonvat N, Taegtmeyer H, Margulies KB, Hammock BD, Despa F. 2014. Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model. J Am Heart Assoc 3(4):doi:10.1161/JAHA.114.001015 PMID:25146704 PMCID:PMC4310392

2013

• Liu J, Lin Y, Qiu H, Morisseau C, Rose TE, Hwang SH, Chiamvimonvat N, Hammock BD. 2013. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. European Journal of Pharmaceutical Sciences 48(4-5):619-627. doi:10.1016/j.ejps.2012.12.013 PMID:23291046 PMCID:PMC3596469
• Sirish P, Li N, Liu J, Lee KS, Hwang SH, Qiu H, Zhao C, Ma S, Lopez JE, Hammock BD, Chiamvimonvat N. 2013. Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proc Natl Acad Sci U S A 110(14):5618-5623. doi:10.1073/pnas.1221972110 PMID:23493561 PMCID:PMC3619365
• Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif A, Liu J, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. 2013. Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II dependent hypertension. J Cardiovasc Pharmacol 62(3):285-297. doi:10.1097/FJC.0b013e318298e460 PMID:23676336 PMCID:PMC3773051

2012

• Cherednichenko G, Zhang R, Bannister RA, Timofeyev V, Li N, Fritsch EB, Feng W, Barrientos G, Schebb N, Hammock BD, Beam KG, Chiamvimonvat N, Pessah IN. 2012. Triclosan impairs excitation-contraction coupling and Ca2+ dynamics in striated muscle. Proc Natl Acad Sci U S A 109(35):14158-14163. doi:10.1073/pnas.1211314109 PMID:22891308 PMCID:PMC3435154
• Qiu H, Liu J, Wei D, Li N, Yamoah EN, Hammock BD, Chiamvimonvat N. 2012. Cardiac-generated prostanoids mediate cardiac myocyte apoptosis after myocardial ischaemia. Cardiovasc Res 95(3):336-345. doi:10.1093/cvr/cvs191 PMID:22707158 PMCID:PMC3400359

2011

• Li YY, Liu J, Harris TR, Sirish P, Hammock BD, Chiamvimonvat N. 2011. Use of metabolomics profiling in the study of arachidonic acid metabolism in cardiovascular disease. American Journal of Cardiology 17:42-46. doi:10.1111/j.1751-7133.2010.00209.x PMID:21272227 PMCID:PMC3583533
• Liu J, Qiu H, Moisseau C, Hwang SH, Tsai H, Ulu A, Chiamvimonvat N, Hammock BD. 2011. Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicol Appl Pharmacol 255:200-206. doi:10.1016/j.taap.2011.06.017 PMID:21741984 PMCID:PMC3156297
• Qiu H, Li N, Liu J, Harris TR, Hammock BD, Chiamvimonvat N. 2011. Soluble epoxide hydrolase inhibitors and heart failure. Cardiovasc Ther 29(2):99-111. doi:10.1111/j.1755-5922.2010.00150.x PMID:20433684 PMCID:PMC3325372

2010

• Liu J, Li N, Yang J, Li N, Qiu H, Ai D, Chiamvimonvat N, Zhu Y, Hammock BD. 2010. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A 107(39):17017-17022. doi:10.1073/pnas.1011278107 PMID:20837537 PMCID:PMC2947894

2009

• Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, Zhu Y. 2009. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 106(2):564-569. doi:10.1073/pnas.0811022106 PMID:19126686 PMCID:PMC2626743
• Li N, Liu J, Timofeyev V, Qiu H, Hwang SH, Tuteja D, Lu L, Yang J, Mochida H, Low R, Hammock BD, Chiamvimonvat N. 2009. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. J Mol Cell Cardiol 47(6):835-845. doi:10.1016/j.yjmcc.2009.08.017 PMID:19716829 PMCID:PMC3290524

2007

• Chiamvimonvat N, Ho C, Tsai H, Hammock BD. 2007. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50(3):225-237. doi:10.1097/FJC.0b013e3181506445 PMID:17878749

2006

• Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai H, Kim I, Tuteja D, Mateo RP, Singapuri A, Davis BB, Low R, Hammock BD, Chiamvimonvat N. 2006. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103(49):18733-18738. PMID:17130447